Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manmohan Gupta

Rheumatology Macon, GA Medical Doctor

NPI 1467569681 CMS profile 248549

770 Pine St, Suite 440, Macon, GA 31201

Open in the dashboard

General payments

$6,888

272 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manmohan Gupta of Macon, GA is reported in the CMS Open Payments database as having received $6,888 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $461 12
2024 General $573 26
2023 General $1,148 41
2022 General $1,382 54
2021 General $870 44
2020 General $1,099 44
2019 General $1,355 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manmohan Gupta
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Manmohan Gupta were reported at $461. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Manmohan Gupta Rheumatology median Middle half National median
2019 $1,355 $744 $153–$2,687 $163
2020 $1,099 $462 $98–$2,027 $114
2021 $870 $531 $101–$2,153 $132
2022 $1,382 $627 $125–$2,303 $149
2023 $1,148 $741 $145–$2,524 $160
2024 $573 $830 $166–$2,660 $164
2025 $461 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,325 91 payments
  2. Janssen Biotech, Inc. $865 29 payments
  3. UCB, Inc. $624 34 payments
  4. Amgen Inc. $573 23 payments
  5. Horizon Therapeutics plc $439 24 payments
  6. Aurinia Pharma U.S., Inc. $359 5 payments
  7. Novartis Pharmaceuticals Corporation $195 9 payments
  8. Lilly USA, LLC $180 11 payments
  9. E.R. Squibb & Sons, L.L.C. $169 9 payments
  10. GlaxoSmithKline, LLC. $167 3 payments
  11. Other $991 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,691 267 payments
  2. Education $197 5 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,038 37 payments
  2. HUMIRA $682 29 payments
  3. SIMPONI $538 21 payments
  4. Cimzia $533 30 payments
  5. SIMPONI ARIA $532 20 payments
  6. STELARA $511 19 payments
  7. REMICADE $490 18 payments
  8. LUPKYNIS $359 5 payments
  9. TREMFYA $349 9 payments
  10. SKYRIZI $347 17 payments
  11. Other $3,541 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,490

Median for Rheumatology: 1,511

Drug cost

$804,443

Median for Rheumatology: $1,139,948

Branded share of claims

22.1%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 46 $378,885
Cimzia (2 Pack) Certolizumab Pegol Brand 17 $136,277
Rinvoq Upadacitinib Brand 18 $113,904
Xeljanz Xr Tofacitinib Citrate Brand 14 $79,676
Simponi Golimumab Brand 12 $69,634
Hydroxychloroquine Sulfate Generic 237 $11,890
Methotrexate Methotrexate Sodium Brand 223 $5,016
Prednisone Generic 373 $2,101
Pilocarpine Hcl Generic 39 $1,365
Colchicine Generic 12 $1,049

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$84,811

Of which drugs: $300

Medicare patients

161

Average age 73

Services billed

3,163

106 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Chronic kidney disease 36%
Ischemic heart disease 28%
Osteoporosis 26%
Depression 25%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 79 390 $300

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $154
$154 — —
RINVOQ
  • AbbVie, Inc. $116
$116 18 —
TREMFYA
  • Janssen Biotech, Inc. $72
$72 — —
KRYSTEXXA
  • Amgen Inc. $55
$55 — —
Bimzelx
  • UCB, Inc. $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record